Wells Fargo initiated coverage of Insmed with an Overweight rating and $55 price target. The analyst sees a “promising” risk-reward for the stock based on the company’s “strong” Arikayce revenue growth and positive Brensocatib and TPIP, or treprostinil palmitil inhalation powder, outlook.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on INSM:
- Insmed reinstated with an Overweight at JPMorgan
- Cantor Fitzgerald biotech analyst holds an analyst/industry conference call
- Insmed price target raised to $35 from $33 at Mizuho
- Insmed Reports Third-Quarter 2023 Financial Results and Provides Business Update
- Insmed reports Q3 EPS ($1.11), consensus ($1.12)